LCB-2151
LCB-2151 (Compound 2), a nucleoside analogue, is an anticancer agent. LCB-2151 disrupts the two primary sources of ATP production (glycolysis and mitochondrial oxidative phosphorylation), reducing the bioenergetic capacity of KRAS-mutated pancreatic cancer cells and inducing ROS formation. LCB-2151 effectively inhibits key enzymes (such as CACT and CPT2) in glycolysis, the TCA cycle and fatty acid β-oxidation. LCB-2151 has significant cytotoxicity and induces cells apoptosis. LCB-2151 can be used for radiation therapy of cancers research[1].
Product Specifications
CAS Number
2211175-99-2
UNSPSC
12352100
Target
Apoptosis; Mitochondrial Metabolism; Oxidative Phosphorylation; Reactive Oxygen Species (ROS)
Related Pathways
Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Field of Research
Cancer
Smiles
OC[C@@]1(C)C(F)(F)[C@H](N2C(N=C(NC(CC(C)(C)CC[C@@H](SCC3=CC=C(C(F)(F)F)C=C3)CCSCC4=CC=C(C(F)(F)F)C=C4)=O)C=C2)=O)O[C@@H]1CO
Molecular Formula
C37H43F8N3O5S2
Molecular Weight
825.87
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Monoclonal Anti-Human free prostate specific antigen (fPSA) IgG # 3 aff pure
